Home > Compound List > Product Information
Fadrozole hydrochloride_Molecular_structure_CAS_102676-31-3)
Click picture or here to close

Fadrozole hydrochloride

Catalog No. F3806 Name Sigma Aldrich
CAS Number 102676-31-3 Website http://www.sigmaaldrich.com
M. F. C14H14ClN3 Telephone 1-800-521-8956
M. W. 259.73406 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 71213

SYNONYMS

IUPAC name
4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile hydrochloride
IUPAC Traditional name
fadrozole hydrochloride
Synonyms
CGS 16949A
4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)-benzonitrile
Afema

DATABASE IDS

MDL Number MFCD00866239
CAS Number 102676-31-3

PROPERTIES

Empirical Formula (Hill Notation) C14H13N3·HCl
Purity ≥98% (HPLC)
Apperance powder
Solubility DMSO: >20 mg/mL
GHS Pictograms GHS06
GHS Pictograms GHS08
GHS Signal Word Danger
GHS Hazard statements H301-H361
European Hazard Symbols Harmful Harmful (Xn)
MSDS Link Download
Personal Protective Equipment dust mask type N95 (US), Eyeshields, Faceshields, Gloves
GHS Precautionary statements P281-P301 + P310
RID/ADR UN 2811 6.1/PG 3
Risk Statements 63-22
RTECS DI4952500
Safety Statements 36/37
Storage Temperature room temp
Hazard Class 6.1
UN Number 2811
Packing Group 3
German water hazard class 2

DETAILS

Description (English)
Biochem/physiol Actions
Fadrozole is a nonsteroidal aromatase inhibitor. Fadrozole is a very potent and highly selective inhibitor of the aromatase enzyme system in vitro and estrogen biosynthesis in vivo. It inhibited the conversion of [4-14C]androstenedione to [4-14C]estrone by human placental microsomes in a competitive manner (Ki = 1.6 nM). At a substrate concentration 3-fold the Km, Fadrozole was 180 times more potent, as an inhibitor, than aminoglutethimide (Cat. No. A9657), exhibiting half-maximal inhibition at 1.7 nM as compared to 0.3 μM. In vivo, Fadrozole lowered ovarian estrogen synthesis by gonadotropin-primed, androstenedione treated, immature rats by 90% at a dose of 260 μg/kg (PO). In vivo, Fadrozole leads to sequelae of estrogen deprivation (e.g. regression of DMBA-induced mammary tumors) without causing adrenal hypertrophy in adult rats. It blocked aromatase by 50% in human breast cancer homogenates, live breast cancer cells, human placental microsomes, and porcine ovarian microsomes at concentrations of 0.008 to 0.02 μM.
Description (简体中文)
Biochem/physiol Actions
Fadrozole is a nonsteroidal aromatase inhibitor. Fadrozole is a very potent and highly selective inhibitor of the aromatase enzyme system in vitro and estrogen biosynthesis in vivo. It inhibited the conversion of [4-14C]androstenedione to [4-14C]estrone by human placental microsomes in a competitive manner (Ki = 1.6 nM). At a substrate concentration 3-fold the Km, Fadrozole was 180 times more potent, as an inhibitor, than aminoglutethimide (Cat. No. A9657), exhibiting half-maximal inhibition at 1.7 nM as compared to 0.3 μM. In vivo, Fadrozole lowered ovarian estrogen synthesis by gonadotropin-primed, androstenedione treated, immature rats by 90% at a dose of 260 μg/kg (PO). In vivo, Fadrozole leads to sequelae of estrogen deprivation (e.g. regression of DMBA-induced mammary tumors) without causing adrenal hypertrophy in adult rats. It blocked aromatase by 50% in human breast cancer homogenates, live breast cancer cells, human placental microsomes, and porcine ovarian microsomes at concentrations of 0.008 to 0.02 μM.

REFERENCES